Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Atrophy of the Mammillary Bodies in Mild Cognitive Impairment
Aging, Dementia, and Behavioral Neurology
Aging and Dementia Posters (7:00 AM-5:00 PM)
048
To determine if mammillary bodies (MB) are altered in subjects with mild cognitive impairment (MCI)
MB are directly linked to brain regions essential for memory including the hippocampus. Animal studies have found that lesioning MB can disrupt hippocampal function and memory. Clinically, MB atrophy has been reported in various amnestic disorders including Alzheimer’s disease (AD); however, whether MB atrophy occurs early in AD such as during the MCI stage is unclear.
This cross-sectional study involved community dwelling volunteers recruited for the Imaging and Genetic Biomarkers for AD (ImaGene) study. All subjects (n=124) were 50 years or older, able to carry out all activities of independent living (non-demented), and had 1.5T 3D T1-weighted structural magnetic resonance imaging (MRI) scans for analysis. Global clinical dementia rating (CDR) scores categorized subjects as cognitively normal (CN, CDR=0, n=51) or MCI (CDR=0.5, n=73). Average grey matter densities for the MB, hippocampus, and cerebellar vermis were measured by voxel-based morphometry (SPM8 with MarsBaR toolbox). In parallel, MB volumes were measured by a manual segmentation protocol developed in-house (MRIcron) and corrected for intracranial volume.

Compared to CN subjects, MCI subjects had significantly lower grey matter densities in the MB (CN: 0.259±0.010, MCI: 0.192±0.012, p<0.01) and hippocampus (CN: 0.724±0.041, MCI: 0.672±0.077, p<0.001) but not in the cerebellar vermis (p>0.05). The differences in the MB grey matter densities between CN and MCI were greater in magnitude than the hippocampus (p<0.05). Total MB volume was significantly lower in MCI subjects compared to CN subjects (CN: 0.102±0.016 cm3, MCI: 0.0914±0.017 cm3, p<0.001) and were significantly associated with CDR Sum of Box scores after adjusting for age, sex, and education (β=-0.19, p=0.022).
Although these findings need verification in longitudinal studies in subjects with biomarker-defined AD, these findings suggest that MB atrophy is an early manifestation of AD.
Authors/Disclosures
Yushan Pan
PRESENTER 		Ms. Pan has nothing to disclose.
No disclosure on file
Gloria Chiang Gloria Chiang has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Life Molecular Imaging. Gloria Chiang has received personal compensation in the range of $0-$499 for serving as a Consultant for Alnylam. The institution of Gloria Chiang has received research support from Minoryx Therapeutics. The institution of Gloria Chiang has received research support from National Institutes of Health. Gloria Chiang has received personal compensation in the range of $5,000-$9,999 for serving as a speaker with Efficient CME. Gloria Chiang has received personal compensation in the range of $500-$4,999 for serving as a speaker with PeerView.
Costantino Iadecola, MD (Weill Cornell Medicine) Dr. Iadecola has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Broadview Ventures.
No disclosure on file
Liana Apostolova, MD, FÂ鶹´«Ã½Ó³»­ (Indiana University School of Medicine) Dr. Apostolova has received personal compensation in the range of $500-$4,999 for serving as a Consultant for NIH. Dr. Apostolova has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Apostolova has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Apostolova has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for siemens. Dr. Apostolova has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eisai. Dr. Apostolova has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alnylam. Dr. Apostolova has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Alzheimer Association. The institution of Dr. Apostolova has received research support from Roche Diagnostics. The institution of Dr. Apostolova has received research support from NIA. The institution of Dr. Apostolova has received research support from Alzheimer Association. The institution of Dr. Apostolova has received research support from AVID radiopharmaceuticals. The institution of Dr. Apostolova has received research support from Life Molecular Imaging. Dr. Apostolova has a non-compensated relationship as a advisor with FDA that is relevant to Â鶹´«Ã½Ó³»­ interests or activities.
Makoto Ishii, MD, PhD (University of Texas Southwestern Medical Center) Dr. Ishii has stock in Regeneron Pharmaceuticals. The institution of Dr. Ishii has received research support from NIH. The institution of Dr. Ishii has received research support from BrightFocus Foundation. The institution of Dr. Ishii has received research support from Alzheimer's Association. Dr. Ishii has received personal compensation in the range of $0-$499 for serving as a Author/Contributor with Relias Media.